Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

PLX PHARMA INC.

(PLXP)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

PLx Pharma Inc. to Discuss 2021 First Quarter Financial Results on May 14, 2021 Conference Call and Provide Business Update

05/03/2021 | 04:30pm EDT

SPARTA, N.J., May 03, 2021 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard™ drug delivery platform designed to provide more effective and safer products, with its lead products VAZALORE™ 325 mg and VAZALORE™ 81 mg (referred to together as “VAZALORE”), announced today that the Company will release its 2021 first quarter financial results on Friday, May 14, 2021, before the U.S. financial markets open.

Natasha Giordano, President and Chief Executive Officer, and Rita O’Connor, Chief Financial Officer, will host a conference call to discuss the results and provide a business update as follows:

DateFriday, May 14, 2021
Time8:30 a.m. ET
Toll free (U.S.)(866) 394-2901
International
Conference ID
(616) 548-5567
6238639
Webcast (live and replay)www.plxpharma.com under the ‘Investor Relations’ section.

A replay of the conference call will be available for two weeks after the call's completion by dialing (855) 859-2056 (U.S.) or (404) 537-3406 (International). The conference ID for the replay is 6238639. The archived webcast will be available for 30 days via the aforementioned URL.

About VAZALORE
VAZALORE is an FDA-approved liquid-filled aspirin capsule that provides patients with vascular disease and diabetic patients who are candidates for aspirin therapy based on physician recommendation, with fast, reliable and predictable platelet inhibition as compared to enteric-coated aspirin. It also reduces the risk of stomach erosions and ulcers, as compared to immediate-release aspirin, common in an acute setting.

About PLx Pharma Inc.
PLx Pharma Inc. is a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard™ drug delivery platform to provide more effective and safer products. The PLxGuard drug delivery platform works by targeting the release of active pharmaceutical ingredients to various portions of the gastrointestinal (GI) tract. PLx believes this platform has the potential to improve the absorption of many drugs currently on the market or in development, and to reduce the risk of stomach erosions and ulcers associated with certain drugs.

To learn more about PLx Pharma Inc. and its pipeline, please visit www.plxpharma.com.

Contact
Investor Relations:
Lisa M. Wilson, In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com
Source: PLx Pharma Inc.


Primary Logo


ę GlobeNewswire 2021
All news about PLX PHARMA INC.
08/03PLX PHARMA : to Launch Vazalore in 8,000 CVS Stores in August
MT
08/02PLx Pharma Inc.'s VAZALORE to Launch in Nearly 8,000 CVS Stores this Month
GL
08/02PLx Pharma Inc.’s VAZALORE to Launch in Nearly 8,000 CVS Stores this Month
CI
07/27PLX PHARMA : to Make Vazalore Available in Over 2,400 Rite Aid Stores in August
MT
07/26PLX PHARMA : VAZALORE to Launch in Over 2,400 Rite Aid Stores in August
AQ
07/26PLx Pharma Inc.’s VAZALORE to Launch in Over 2,400 Rite Aid Stores in August
CI
07/22PLX PHARMA : to Discuss 2021 Second Quarter Financial Results on August 6, 2021 ..
AQ
07/20AFTER HOURS WATCH LIST SCORECARD : Plxp, ppg, ardx
MT
07/20PLx Shares Rise as Walgreens Set to Carry Vazalore in Stores
DJ
07/20SECTOR UPDATE : Health Care Stocks Edge Higher Pre-Bell Tuesday
MT
More news
Financials (USD)
Sales 2021 5,73 M - -
Net income 2021 -27,3 M - -
Net Debt 2021 - - -
P/E ratio 2021 -13,5x
Yield 2021 -
Capitalization 408 M 408 M -
Capi. / Sales 2021 71,2x
Capi. / Sales 2022 15,4x
Nbr of Employees 10
Free-Float 81,8%
Chart PLX PHARMA INC.
Duration : Period :
PLx Pharma Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PLX PHARMA INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Last Close Price 17,77 $
Average target price 21,50 $
Spread / Average Target 21,0%
EPS Revisions
Managers and Directors
Natasha Giordano President, Chief Executive Officer & Director
Rita M. O'Connor CFO, Head-Manufacturing & Supply Chain
Michael J. Valentino Executive Chairman
Gary S. Balkema Independent Director
Kirk K. Calhoun Independent Director
Sector and Competitors
1st jan.Capi. (M$)
PLX PHARMA INC.221.92%408
GILEAD SCIENCES, INC.19.86%87 579
BIONTECH SE408.39%84 970
WUXI APPTEC CO., LTD.41.52%71 929
REGENERON PHARMACEUTICALS21.40%60 737
VERTEX PHARMACEUTICALS-15.55%51 899